CYAD - Celyad to evaluate CYAD-101/KEYTRUDA combo in colorectal cancer

Celyad Oncology ([[CYAD]]) announces a clinical trial collaboration with Merck, wherein Celyad will conduct a Phase 1b KEYNOTE-B79 trial, evaluating its CYAD-101, following FOLFIRI (combination of 5-fluorouracil, leucovorin and irinotecan) preconditioning chemotherapy, with latter's KEYTRUDA (pembrolizumab) in refractory metastatic colorectal cancer patients with microsatellite stable / mismatch-repair proficient disease.CYAD-101 is a non-gene edited allogeneic CAR T therapy designed to avoid graft-versus-host disease (GvHD) via the use of a technology called TIM (T cell receptor inhibitory molecule) that knocks down the immune response responsible for GvHD.In June, the company announced positive updated data from Phase 1 trial, alloSHRINK in patients with relapsed/refractory mCRC who progressed after chemo.

For further details see:

Celyad to evaluate CYAD-101/KEYTRUDA combo in colorectal cancer